NAV-1003
20 Dec 2022
Trial Summary
A first-in-human study to evaluate the safety, tolerability and maximum tolerated dose (MTD) and establish the recommended phase 2 dose (RP2D) of BBP-398, a SHP2 inhibitor, in patients with advanced solid tumors.
Acronym:
NAV-1003
ACTRN/NCT /ethics:
NCT04528836
Scientific title:
First-in-Human Study of the SHP2 Inhibitor BBP-398 in Patients With Advanced Solid Tumors
Sponsor / Cooperative group:
Navire Pharma Inc., a BridgeBio company
Trial & Patient Characteristics
| Cancer Type | Solid cancers |
|---|---|
| Trial Type | Treatment |
| Phase | Phase I |
| Age Range | 18 years and older |
| Sex | All |
| Tumour Stream | - |
| Cancer Stage | Locally Advanced |
| Anticipated Start Date | 2020-11-12 |
| Anticipated End Date | 2023-10-01 |
Participating Hospitals
| Hospital | Cancer Research SA |
|---|---|
| Clinical Trial Coordinator | Kelly Mead/Kate Penda |
| admin@cancerresearchsa.com.au | |
| Phone | 08 8359 2565 |
| Principal Investigator | Dr Rohit Joshi/Dr Vineet Kwatra |
| Recruitment Status | Recruiting |